Zacks Investment Research upgraded shares of Mesa Laboratories (NASDAQ:MLAB) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning.
According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “
Separately, TheStreet upgraded shares of Mesa Laboratories from a c+ rating to a b rating in a research note on Monday, November 6th.
Mesa Laboratories (NASDAQ MLAB) traded up $0.82 during trading hours on Tuesday, reaching $133.66. 4,394 shares of the company traded hands, compared to its average volume of 14,478. The firm has a market cap of $502.10, a PE ratio of 48.25 and a beta of 0.42. Mesa Laboratories has a 1 year low of $113.57 and a 1 year high of $169.80. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48.
Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). The company had revenue of $22.95 million for the quarter, compared to analyst estimates of $25.50 million. Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. research analysts forecast that Mesa Laboratories will post 2.47 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s dividend payout ratio is 23.10%.
Several hedge funds have recently made changes to their positions in MLAB. Capital Analysts LLC acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $128,000. SG Americas Securities LLC acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $131,000. Voya Investment Management LLC acquired a new position in shares of Mesa Laboratories in the 2nd quarter valued at $221,000. Westfield Capital Management Co. LP acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $239,000. Finally, BT Investment Management Ltd acquired a new position in shares of Mesa Laboratories in the 2nd quarter valued at $277,000. Institutional investors own 69.79% of the company’s stock.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/mesa-laboratories-mlab-upgraded-at-zacks-investment-research.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.